Zai Lab
Junwei Zhang currently serves as Chief of Staff to the CEO and Head of Commercial Strategy, NPP, and Operation Excellence at 再鼎医药 since May 2021. Prior experience includes roles at The Boston Consulting Group as Principal from September 2016 to May 2021, and academic involvement as a Fellow in the Advanced Graduate Leadership Program from September 2013 to May 2016. Junwei Zhang also held positions such as Director of the Scientific Committee for the Connecticut Sino-American Pharmaceutical Association and Co-founder of the Chinese Affiliate Entrepreneurs Club at Yale, which established partnerships with significant venture capitalists. Leadership experience includes serving as President of The Association of Chinese Students and Scholars at Yale, organizing a variety of events that engaged numerous attendees. Junwei Zhang’s educational background includes a PhD in Chemical Engineering from Yale University and a Bachelor's degree in Chemical Engineering from Zhejiang University, along with studies at the University of Cambridge.
This person is not in any teams
This person is not in any offices
Zai Lab
5 followers
Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.